Latest in News & Research
Reflectance Confocal Microscopy Agrees With Histopathology in Lentigo Maligna
Good agreement seen between RCM and histopathology for patients with lentigo maligna/lentigo maligna melanoma undergoing staging excision
AI Model Differentiates Scalp Psoriasis From Seborrheic Dermatitis
Use of deep learning model improves diagnostic performance among nonproficient doctors
Is Oxymetazoline Cream Effective for Erythema-Associated Rosacea?
Review shows once-daily oxymetazoline cream 1.0 percent has noticeable effect on improving rosacea erythema
Does Rituximab Have Lasting Benefit in Patients With Systemic Sclerosis?
Sustained improvements seen in modified Rodnan skin score, percentage of predicted forced vital capacity after one and three courses of rituximab
Diet-Induced Inflammation Not Linked to Psoriasis
Dietary inflammatory index not linked to psoriasis in participants with different population settings
Global Prevalence of Eczema Estimated for Children, Teens
Considerable variation seen in prevalence, with region and income level accounting for some heterogeneity
Difelikefalin Improves Itch Intensity in Notalgia Paresthetica
However, more frequent headache, dizziness, constipation, increased urine output seen for patients receiving difelikefalin versus placebo
Is Collagenase Clostridium Histolyticum-aaes Effective for Thigh Cellulite?
CCH-aaes found to be effective and well tolerated for thigh cellulite, with reduction seen in patient-reported bother due to cellulite
Morphea Activity Measure Reliable, Valid for Disease Activity
Moderately strong correlations seen between MAM and modified Localized Scleroderma Severity Index, Physician Global Assessment of Activity
Measles Outbreak in Ohio Declared Over After 85 Cases
Outbreak declared finished with no new cases after a period of 42 days, or the equivalent of two measles virus incubation periods
Is Dupilumab Beneficial for Treatment of Erythrodermic Atopic Dermatitis?
Significant improvements reported in percentage BSA affected by AD, Eczema Area and Severity Index score, Peak Pruritus Numerical Rating Scale score
Local Recurrence Rate Low With Mohs for Invasive Head, Neck Melanoma
Disease-specific survival was 96.8 and 93.4 percent at five and 10 years, respectively
CDC Reports on Prevalence of Seasonal and Food Allergies, Eczema
18.9 percent of children and 25.7 percent of adults had seasonal allergy; 10.8 and 7.3 percent had eczema in 2021
What Is the Prevalence of Depression, Anxiety Disorders in Alopecia Areata Patients?
Prevalence of depression disorder 9 percent, anxiety disorder 7 to 17 percent; prevalence of disorders lower than depression and anxiety symptom prevalence
Guidelines Issued for Gene Expression Profiling in Cutaneous Melanoma
GEP results can improve prognostic assessment for patients with tumors with uncertainty about adequacy of microstaging
Risk for Subsequent Facial Keratinocyte Carcinoma Lower With Laser Treatment
Nonablative fractional laser-treated patients had lower rate of subsequent facial keratinocyte carcinoma development
Air Pollution Tied to Psoriasis Occurrence
Females, children more sensitive to changes in air pollutants
Health Concepts From PROMs Can Be Classified Into Five Domains for Psoriasis
Most frequently captured domains are social well-being and psychological well-being; no PROM captured all five domains
Guidelines Updated for Topical Treatment of Atopic Dermatitis in Adults
Strong recommendations include use of moisturizers, topical corticosteroids, topical calcineurin inhibitors
Rates of Clinic Visits for Psoriasis Increased for Adults After Wildfires
Air pollution from wildfire linked to modestly increased rates of clinic visits for psoriasis among adults starting five weeks after fire
MPATH-Dx Version 2.0 Simplifies Classification of Melanoma
Updated version simplifies original five-class hierarchy into four classes, including clearly defining classes I and II lesions
Do Outcomes Improve With Lebrikizumab in Atopic Dermatitis?
Improvement seen in IGA(0,1) and in EASI-75 with lebrikizumab plus topical corticosteroids versus placebo plus topical corticosteroids
Risankizumab Safe, Effective at 52 Weeks for Psoriatic Arthritis
Long-term benefits seen in patients with inadequate response/intolerance to biologic or conventional disease-modifying antirheumatic drugs
24 of 1274